Bruker Corp. (NASDAQ:BRKR) CEO Frank H. Laukien acquired 2,124 shares of the company’s stock in a transaction dated Friday, November 25th. The shares were bought at an average cost of $22.90 per share, with a total value of $48,639.60. Following the completion of the acquisition, the chief executive officer now directly owns 37,699,606 shares in the company, valued at approximately $863,320,977.40. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Shares of Bruker Corp. (NASDAQ:BRKR) opened at 23.30 on Wednesday. The company has a market cap of $3.73 billion, a price-to-earnings ratio of 26.33 and a beta of 1.04. Bruker Corp. has a 52 week low of $19.58 and a 52 week high of $29.85. The stock’s 50 day moving average is $21.80 and its 200-day moving average is $23.16.

Bruker Corp. (NASDAQ:BRKR) last released its quarterly earnings data on Wednesday, November 2nd. The company reported $0.32 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.20 by $0.12. Bruker Corp. had a net margin of 9.02% and a return on equity of 26.05%. The business earned $393.90 million during the quarter, compared to analyst estimates of $394.14 million. During the same quarter last year, the business earned $0.19 earnings per share. Bruker Corp.’s quarterly revenue was down .6% compared to the same quarter last year. On average, equities analysts anticipate that Bruker Corp. will post $1.10 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 23rd. Shareholders of record on Monday, December 5th will be given a dividend of $0.04 per share. The ex-dividend date is Thursday, December 1st. This represents a $0.16 annualized dividend and a yield of 0.69%. Bruker Corp.’s dividend payout ratio (DPR) is currently 18.18%.

WARNING: This piece of content was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States and international trademark and copyright law. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2016/11/30/frank-h-laukien-buys-2124-shares-of-bruker-corp-brkr-stock.html.

A number of institutional investors have recently added to or reduced their stakes in BRKR. Capital Fund Management S.A. acquired a new position in Bruker Corp. during the second quarter valued at approximately $10,471,000. State Street Corp raised its position in Bruker Corp. by 27.2% in the first quarter. State Street Corp now owns 1,527,696 shares of the company’s stock valued at $42,770,000 after buying an additional 326,527 shares during the period. Quantitative Investment Management LLC raised its position in Bruker Corp. by 157.7% in the second quarter. Quantitative Investment Management LLC now owns 63,900 shares of the company’s stock valued at $1,453,000 after buying an additional 39,100 shares during the period. Smith Asset Management Group LP acquired a new position in Bruker Corp. during the second quarter valued at approximately $8,928,000. Finally, Wells Fargo & Company MN raised its position in Bruker Corp. by 36.5% in the third quarter. Wells Fargo & Company MN now owns 559,670 shares of the company’s stock valued at $12,677,000 after buying an additional 149,523 shares during the period. Institutional investors and hedge funds own 67.74% of the company’s stock.

A number of analysts have recently issued reports on BRKR shares. Janney Montgomery Scott raised shares of Bruker Corp. from a “neutral” rating to a “buy” rating and set a $28.00 price objective for the company in a report on Wednesday, August 3rd. Leerink Swann started coverage on shares of Bruker Corp. in a report on Thursday, November 10th. They set a “market perform” rating and a $21.00 price objective for the company. Wells Fargo & Co. downgraded shares of Bruker Corp. from an “outperform” rating to a “market perform” rating in a report on Wednesday, August 3rd. Mizuho decreased their target price on shares of Bruker Corp. from $28.00 to $23.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 3rd. Finally, Cantor Fitzgerald reiterated a “buy” rating and issued a $28.00 target price on shares of Bruker Corp. in a research report on Thursday, November 3rd. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $25.73.

About Bruker Corp.

Bruker Corporation is a designer and manufacturer of scientific instruments, and analytical and diagnostic solutions. The Company’s operating segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.

5 Day Chart for NASDAQ:BRKR

Receive News & Stock Ratings for Bruker Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker Corp. and related stocks with our FREE daily email newsletter.